Genetic Study of Obstructive Azoospermia (NCT05631509) | Clinical Trial Compass
UnknownNot Applicable
Genetic Study of Obstructive Azoospermia
China300 participantsStarted 2021-07-01
Plain-language summary
In 1% of men with infertility, obstructive azoospermia (OA) may occur in congenital absence of the vas (CAVD) or idiopathic obstructive azoospermia . Many studies have shown that the pathogenic genes of OA are CFTR and ADGRG2 genes, and the inheritance mode is autosomal recessive. Although the conventional assisted reproductive technology(PESA/TESA) can help these patients have children, male patients who carry mutations of the disease-causing genes (CFTR and ADGRG2) will also pass on their mutations to the next generation, which will increase the risk of male offspring infertility. Therefore, genetic detection of CFTR and ADGRG2 genes is very necessary for CAVD patients before assisted reproduction. Genetic diagnosis plays a key role in preventing the disease to the offspring.
Who can participate
Age range
18 Years – 50 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* No sperm was found after centrifugation for 15min for two or more semen tests, and the interval between two tests was at least 2 weeks.
* Blood FSH is normal;
* Hematostatin b is normal;
* Chromosome karyotype is normal or polymorphic;
* Y chromosome microdeletion did not show the deletion:(main locus);
* Biochemical fructose of seminal plasma : less than the normal value;
* PH of semen \<7.2;
* Transscrotal or transrectal ultrasound: normal testicular size(as measured by B ultrasound), presence or dysplasia of vas deferens and epididymis;
Exclusion Criteria:
* B ultrasound of urinary system suggested abnormal development;
* Transscrotal or Transrectal ultrasound indicated absence of vas deferens or epididymis or seminal vesicle;
* Physical examination showed the following abnormalities: cryptorchidism, tenderness of testis and epididymis;
* The following medical history: genitourinary tract trauma or surgical history; orchitis; epididymitis; Seminal vesicle disease; mumps;
* Laboratory examination: red and white blood cell elevation of semen routine
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
mutation rate
Timeframe: through study completion, an average of 3 year
Trial details
NCT IDNCT05631509
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University